Publication
Article
Supplements and Featured Publications
GOAL
To provide participants with current information about current blood pressure goals and effective use of antihypertensive agents to achieve these goals.
TARGET AUDIENCE
This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, primary care physicians, and specialists in internal medicine and cardiology.
EDUCATIONAL OBJECTIVES
After completing this continuing education activity, the participant should be able to:
CONTINUING MEDICAL EDUCATION ACCREDITATION
The University of Cincinnati College of Medicine designates this activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.
The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Release Date: September 1, 2005. Expiration Date: September 30, 2006.
CONTINUING PHARMACY EDUCATION ACCREDITATION
Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-05-011-H04. Release Date: September 1, 2005. Expiration Date: September 1, 2006.
FUNDING
This program is supported by an unrestricted educational grant from Sankyo Pharma Inc.
CME/CE QUESTIONS
Continuing Medical Education Accreditation
The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.
The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.
Continuing Pharmacy Education Accreditation
Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-05-011-H04.
Instructions
After reading "Healthcare Economics of Achieving JNC 7 Blood Pressure Goals in Clinical Practice," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.
1. Ischemic heart disease mortality has been shown to increase linearly with age starting at systolic/diastolic blood pressures of:
2. Which of the following statements about the findings of the most recent National Health and Nutrition Examination Survey (NHANES) is true?
3. Which of the following statements about blood pressure is true?
4. Which of the following is not a feature of the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)?
5. JNC 7 lists compelling reasons for specific classes of antihypertensive drugs. Diabetes is a compelling indication for all of the following except a(an):
6. Which of the following is not a JNC 7 recommendation about drug therapy?
7. The most recent NHANES data show a hypertension control rate in the United States of 31%. The Healthy People 2010 goal is:
8. In 2004, the cost of hypertension in the United States was estimated to be:
9. Antihypertensive therapy dramatically reduces cardiovascular morbidity and mortality. The State of Health Care Quality: 2004 report showed the greatest reduction in:
10. In a recent study of insured patients with diabetes and hypertension, the most frequently used antihypertensive agents were:
11. Which of the following statements is true?
12. Which of the following statements is false?
13. In the Hypertension Optimal Treatment study, about _______ were able to achieve a goal diastolic blood pressure of =80 mm Hg on monotherapy.
14. Which of the following statements about angiotensin II is false?
15. Which of the following statements about ARBs is false?
16. In the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study, about _____ of patients who received the 300-mg/day dosage achieved normoalbuminuria.
17. In the Losartan Intervention For Endpoint reduction in hypertension study:
18. The Valsartan Antihypertensive Long-term Use Evaluation showed that:
19. In a comparison of the starting doses of 4 ARBs, more patients achieved the blood pressure goal of =140/90 mm Hg in the group treated with:
20. Overall, clinical trials of ARBs have shown:
CE QUIZ
For Pharmacists
ANSWER CARD INSTRUCTIONS
Testing and Grading Procedures
Pharmacy Times,
Please photocopy the test form for additional test takers.
Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-05-011-H04. The program is available for CE credit through September 1, 2006.
Answer card and evaluation form for Pharmacists follow on page S232.
SUPPLEMENT POLICY STATEMENT
The American Journal of Managed Care
Standards for Supplements to
The American Journal of Managed Care
Journal
The American Journal of Managed Care
All supplements to are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to will:
The American Journal of Managed Care
Publisher
's Note
The American Journal of
Managed Care
: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of . Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.